With a market capitalization of $8,868,574,737, Teva Pharmaceutical Industries Ltd has a greater market value than 87.25% of US stocks.
Revenue growth over the past 12 months for Teva Pharmaceutical Industries Ltd comes in at -10.43%, a number that bests only 15.93% of the US stocks we're tracking.
Teva Pharmaceutical Industries Ltd's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 21.01%, greater than the shareholder yield of 83.84% of stocks in our set.
If you're looking for stocks that are quantitatively similar to Teva Pharmaceutical Industries Ltd, a group of peers worth examining would be HAS, BC, GRA, TRIB, and TG.
TEVA's SEC filings can be seen here. And to visit Teva Pharmaceutical Industries Ltd's official web site, go to www.tevapharm.com.
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) Company Bio
Teva Pharmaceuticals manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The company was founded in 1901 and is based in Petach Tikva, Israel.
TEVA Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Teva Pharmaceutical Industries Ltd with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Teva Pharmaceutical Industries Ltd ranked in the 0th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 100%. The most interesting components of our discounted cash flow analysis for Teva Pharmaceutical Industries Ltd ended up being:
In the past 5.04 years, Teva Pharmaceutical Industries Ltd has a compound free cash flow growth rate of -0.44%; that's better than just 4.98% of cash flow producing equities in the Healthcare sector, where it is classified.
24% of the company's capital comes from equity, which is greater than only 14.78% of stocks in our cash flow based forecasting set.
Teva Pharmaceutical Industries Ltd's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -0.55. This coverage rate is greater than that of merely 15.54% of stocks we're observing for the purpose of forecasting via discounted cash flows.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as TEVA, try AGHC, ALC, AMPH, CSII, and ELAN.